Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Danaher Community
NYSE:DHR Community
1
Narratives
written by author
0
Comments
on narratives written by author
79
Fair Values set
on narratives written by author
Create a narrative
Danaher
Popular
Undervalued
Overvalued
Community Investing Ideas
Danaher
AN
AnalystConsensusTarget
Consensus Narrative from 24 Analysts
Bioprocessing Capacity Expansion And 80% Recurring Revenue Will Drive Success
Key Takeaways Investment in bioprocessing and new technologies is expected to boost long-term growth and strengthen market position through innovation and strategic initiatives. Strong recurring revenue model and effective cost management are likely to enhance stable, predictable revenue streams and improve operating margins.
View narrative
US$247.17
FV
23.5% undervalued
intrinsic discount
6.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
48
users have followed this narrative
14 days ago
author updated this narrative
Your Valuation for
DHR
DHR
Danaher
Your Fair Value
US$
Current Price
US$189.18
47.6% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
32b
2015
2018
2021
2024
2025
2027
2030
Revenue US$32.0b
Earnings US$5.1b
Advanced
Set Fair Value